Articles From: Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies to Gamco Global Gold, Natural Resources & Income Trust by Gabelli to Redeem Its Remaining Outstanding 6.625% Series a Cumulative Preferred Shares


2013/4/29
- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 - NORCROSS, Ga.
Sign-up for Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies investment picks
2013/2/19
Galectin Therapeutics (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug discovery program with Dr.
Sign-up for Galectin Therapeutics Announces Discovery Program for New Anti-Galectin Drugs in Collaboration with the University of Georgia investment picks
2013/1/31
Galectin Therapeutics (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.
Sign-up for Galectin Therapeutics Inc. Announces Submission of an Investigational New Drug (IND) Application for the Treatment of Fatty Liver Disease investment picks
2013/5/10
NORCROSS, Ga.
Sign-up for Galectin Therapeutics Reports First Quarter 2013 Financial Results investment picks
2013/3/29
NORCROSS, Ga.
Sign-up for Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results investment picks
2013/5/15
ATLANTA , May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013 , to provide an update following the Company's Annual Meeting of Shareholders.
Sign-up for Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders investment picks
2013/4/17
-- Abstract Accepted for Presentation at the International Liver Congress 2013 --
Sign-up for Galectin Therapeutics to Present New Data on the Treatment of Liver Fibrosis and Cirrhosis investment picks
2013/4/4
Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for Biotech" and Curing Big Diseases NORCROSS, Ga.
Sign-up for Galectin Therapeutics: Turning Atlanta into America's Next Silicon Valley investment picks
2013/3/18
Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients.
Sign-up for Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain investment picks
2013/5/9
Abstral ® (fentanyl) Sublingual Tablets are an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impacts the majority of cancer patients at some point in their care.
Sign-up for Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting investment picks
2013/3/14
LAKE OSWEGO, Ore., March 14, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that independent research firm, Frost & Sullivan, has recognized Galena Biopharma with the 2013 Global Frost & Sullivan Award for New Product Innovation.
Sign-up for Galena Biopharma Receives 2013 Global Frost & Sullivan Award for New Product Innovation for NeuVax(TM) investment picks
2013/3/12
Operating loss from continuing operations for the year ended December 31, 2012 was $21.2 million, including $1.8 million in stock-based compensation.
Sign-up for Galena Biopharma Reports Year-End 2012 Financial Results investment picks
2013/4/24
LAKE OSWEGO, Ore., April 24, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J.
Sign-up for Galena Biopharma to Present at the 12th Annual Needham Healthcare Conference investment picks
2013/2/5
LAKE OSWEGO, Ore., Feb.
Sign-up for Galena Biopharma to Present at the 15th Annual Bio CEO & Investor Conference investment picks
2013/4/16
LAKE OSWEGO, Ore., April 16, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark W.
Sign-up for Galena Biopharma to Present at the 2013 BIO International Convention investment picks
2013/3/29
LAKE OSWEGO, Ore., March 29, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J.
Sign-up for Galena Biopharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference investment picks
2013/3/11
LAKE OSWEGO, Ore., March 11, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J.
Sign-up for Galena Biopharma to Present at the 25th Annual ROTH Conference investment picks
2013/3/4
LAKE OSWEGO, Ore., March 4, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark W.
Sign-up for Galena Biopharma to Present at the 7th Annual Bio-Europe International Partnering Conference investment picks
2013/4/15
LISBON --Portuguese oil company Galp Energia SGPS SA (GALP.LB) said in a trading update Monday that crude processed for refining in the first quarter rose 6.3% on the year.
Sign-up for Galp 1Q Refining up 6.3% on Year at 21.5 Million Barrels investment picks
2013/4/29
LISBON --Portuguese oil company Galp Energia SGPS SA (GALP.LB) said on Monday first-quarter adjusted net profit rose 51.5% helped by an increase in oil output.
Sign-up for Galp Adjusted Net Profit up on Higher Oil Output investment picks
2013/2/5
GAMCO Investors, Inc. (NYSE: GBL) announced today that its Board of Directors approved a quarterly dividend of $0.05 per share to all of its Class A and Class B shareholders, payable on March 26, 2013 to its Class A and Class B shareholders of record on March 12, 2013.
Sign-up for GAMCO Board Approves a First Quarter Dividend of $0.05 Per Share and Authorizes Additional 500,000 Shares for Stock Buyback investment picks
2013/5/7
GAMCO Investors, Inc. (NYSE: GBL) announced today that its Board of Directors approved a quarterly dividend of $0.05 per share to all of its Class A and Class B shareholders, payable on June 25, 2013 to its Class A and Class B shareholders of record on June 11, 2013.
Sign-up for GAMCO Board Approves Its Quarter Dividend of $0.05 Per Share investment picks
2013/5/2
GAMCO Investors, Inc. (GAMCO) (NYSE: GBL) announced today it has adopted a Shareholder Designated Charitable Contribution program for all registered Class A and Class B shareholders.
Sign-up for GAMCO Establishes Shareholder Designated Charitable Contribution Program investment picks
2013/3/12
The Board of Trustees of the GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT:GGN) (the “Fund”) has authorized the partial redemption of 2,000,000 of its outstanding 6.625% Series A Cumulative Preferred Shares (the “Series A Preferred Shares”). The redemption date is Thursday, April 11, 2013, and the redemption price is $25.069 per Series A Preferred Share, which is equal to the liquidation preference of $25.00 per Series A Preferred Share, plus accumulated but unpaid dividends of $0.069. From and after the redemption date, the Series A Preferred Shares to be redeemed will no longer be deemed outstanding, dividends will cease to accrue, and all the rights of the Series A Preferred Shareholders with respect to the redeemed Series A Preferred Shares will cease, except the right to receive the redemption price.
Sign-up for GAMCO Global Gold, Natural Resources & Income Trust by Gabelli Announces Partial Redemption of Its 6.625% Series a Cumulative Preferred Shares investment picks
2013/5/17
The Board of Trustees of the GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT:GGN) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions.
Sign-up for GAMCO Global Gold, Natural Resources & Income Trust by Gabelli Continues Monthly Distributions, Declaring Distributions of $0.12 Per Share investment picks
2013/2/28
The Board of Trustees of the GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT:GGN) (the “Fund”) approved the continuation of its policy of paying monthly cash distributions.
Sign-up for Gamco Global Gold, Natural Resources & Income Trust by Gabelli Continues Monthly Distributions, Declaring Distributions of $0.12 Per Share investment picks
2013/5/3
The Board of Trustees of the GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT:GGN) (the “Fund”) is pleased to announce the underwritten offering of 4 million 5.00% Series B Cumulative Preferred Shares (“Series B Preferred Shares”) at a public offering price of $100 million.
Sign-up for Gamco Global Gold, Natural Resources & Income Trust by Gabelli is Pleased to Announce the Offering of $100 Million of 5.00% Series B Cumulative Preferred Shares investment picks
2013/5/7
GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT: GGN) (the “Fund”) is pleased to announce the completion of an underwritten offering of 4 million 5.00% Series B Cumulative Preferred Shares (the “Series B Preferred Shares”) at a public offering price of $100 million.
Sign-up for GAMCO Global Gold, Natural Resources & Income Trust by Gabelli Issues $100 Million of 5.00% Series B Cumulative Preferred Shares investment picks
2013/5/13
The Board of Trustees of the GAMCO Global Gold, Natural Resources & Income Trust by Gabelli (NYSE MKT:GGN) (the “Fund”) authorized the redemption of all remaining outstanding shares of the Fund’s 6.625% Series A Cumulative Preferred Shares (the “Series A Preferred Shares”). The redemption date is June 12, 2013, and the redemption price is $25.35425 per Series A Preferred Share, which is equal to the liquidation preference of $25.00 per Series A Preferred Share, plus accumulated but unpaid dividends of $0.35425 through the redemption date.
Sign-up for Gamco Global Gold, Natural Resources & Income Trust by Gabelli to Redeem Its Remaining Outstanding 6.625% Series a Cumulative Preferred Shares investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies to Gamco Global Gold, Natural Resources & Income Trust by Gabelli to Redeem Its Remaining Outstanding 6.625% Series a Cumulative Preferred Shares
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity